Background This is an update of the original Cochrane Review, last published in 2012 (Loy
2012). Children and youths with disruptive behaviour disorders may present to health …

OBJECTIVE:: Despite increasing use of psychotropic medications in children and
adolescents, data regarding their efficacy and safety are limited. Endocrine and metabolic …

Current evidence supports a lower tardive dyskinesia risk for second-generation
antipsychotics than for first-generation antipsychotics. Tardive dyskinesia incidence was …

Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize
Outcomes | Focus Skip to main content Go to homepage Go to homepage Close DSM Library …

BACKGROUND: The use of antipsychotics, especially second-generation antipsychotics
(SGAs), for children with mental health disorders in Canada has increased dramatically over …

Objective Although combination pharmacotherapy is common in child and adolescent
psychiatry, there has been little research evaluating it. The value of adding risperidone to …

Challenging behaviors in persons with intellectual disabilities are primary target for
treatment in mental health clinics and institutions. Furthermore, an increasing number of …

Despite the limited availability of randomized, controlled evidence regarding the efficacy and
safety of second-generation antipsychotics (SGAs) in pediatric populations [1, 2], this class …

OBJECTIVE: The short-term benefit of risperidone in ameliorating severe disruptive behavior
in pediatric patients with autism spectrum disorders is well established; however, only one …

When taking antipsychotic medications, children and adolescents seem to have a higher risk
than adults for experiencing adverse events such as extrapyramidal symptoms, prolactin …